ArticleFrontiers in neurology2025
Efficacy evaluation and mechanistic investigation of transcutaneous auricular vagus nerve stimulation in enhancing the therapeutic effects of semaglutide and reducing its gastrointestinal side effects: a randomized controlled trial protocol.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic disorder with serious complications. Semaglutide, a GLP-1 receptor agonist, improves glycemic control and weight but is limited by gastrointestinal (GI) side effects, notably nausea, vomiting, and diarrhea, which impair adherence. Transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive therapy, shows potential in alleviating gastrointestinal symptoms, yet its role in mitigating semaglutide-related side effects and enhancing drug efficacy remains unexplored. Methods: A total of 60 T2DM participants experiencing semaglutide-induced GI side effects will be randomly assigned to a control or intervention group. The control group will receive semaglutide (0.25 mg weekly) plus sham-taVNS, with electrodes attached to the bilateral auricular scapha at 4/20 Hz for 30 min, twice daily. The intervention group will receive semaglutide plus active taVNS, with electrodes on the bilateral cymba and cavum conchae using the same stimulation parameters. Treatment will span two 6-week cycles (12 weeks total). The primary outcome is the Rhodes Index of Nausea, Vomiting, and Retching. Secondary outcomes include gastric electromyography, serological markers, Visual Analogue Scale, and the Simplified Nutritional Appetite Questionnaire. Adverse events will be monitored, and assessments will occur at baseline, week 6, end of treatment, and follow-up. Discussion: This study aims to determine whether taVNS can alleviate semaglutide-induced GI side effects and enhance the therapeutic efficacy of semaglutide. Conclusion: This study protocol has a randomized, sham-controlled design with rigorous internal validity. Limitations include the potential placebo effects, single-center setting, and small sample size. We expect taVNS to alleviate semaglutide-induced GI side effects and potentially enhance its therapeutic efficacy. In conclusion, this trial will provide preliminary evidence on the safety and effectiveness of taVNS as an supplementary therapy to semaglutide in T2DM, informing the design of future larger-scale studies. Clinical trial registration: http://itmctr.ccebtcm.org.cn/en-US, identifier ITMCTR2025001226.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.